Stock listing

NASDAQ:ADRX ADARx Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of ADARx Pharmaceuticals, Inc.

Follow ADARx Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ADRX

$12.79 USD -0.03 (-0.2%)

Close on Nov 20, 2026

Past month -33.9% · daily closes, Sep 25, 2026 – Nov 20, 2026, adjusted for splits
Day range
$12.66 – $14.86 USDNov 20, 2026
Volume
708,823 sharesNov 20, 2026
Market cap
$1.42B USDAt the close on Nov 20, 2026 · price × 110.7M shares outstanding
Traded on an average day
$11.31M USDMedian day 475,714 shares · last 3 months, Sep 25, 2026 – Nov 20, 2026
ADARx Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ADRX · Home$12.79 USD-0.03 (-0.2%)708,823$14.03$14.86$12.66$12.82Close on Nov 20, 2026

Daily closes

Last 3 months, Sep 25, 2026 – Nov 20, 2026 · NASDAQ:ADRX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$12.79-0.03-0.2%$14.03$14.86$12.66708,823
$12.82-1.00-7.2%$13.85$14.84$12.79654,561
$13.82-0.18-1.3%$14.03$14.96$12.90696,893
$14.00-0.20-1.4%$14.22$15.21$13.08667,015
$14.20-0.71-4.8%$14.96$15.21$13.70587,958
$14.91+1.61+12.1%$13.25$16.24$12.87994,874
$13.30-0.27-2.0%$13.73$14.07$13.17509,927
$13.57-0.23-1.7%$13.64$14.30$13.30289,825
$13.80+0.57+4.3%$13.24$13.99$12.70357,025
$13.23-0.06-0.5%$13.73$13.73$12.50439,977
$13.29-1.67-11.2%$14.97$15.39$12.75781,163
$14.96-1.13-7.0%$16.33$16.73$14.85377,795
$16.09+0.33+2.1%$15.78$16.46$15.00378,482
$15.76-1.24-7.3%$16.95$17.01$15.71378,575
$17.00-0.85-4.8%$18.10$18.10$16.30542,258
$17.85-0.10-0.6%$18.00$18.75$17.65402,000
$17.95-0.18-1.0%$18.22$18.36$17.66264,700
$18.13+0.32+1.8%$17.99$18.80$17.71293,600
$17.81+0.18+1.0%$17.77$19.07$17.5099,600
$17.63-0.05-0.3%$17.68$18.33$17.00177,600
$17.68+0.55+3.2%$17.18$17.88$17.18181,500
$17.13-0.55-3.1%$17.58$18.17$17.00441,500
$17.68+0.05+0.3%$17.98$18.55$16.611,074,900
$17.63-0.02-0.1%$17.76$18.33$17.05262,000
$17.65-0.05-0.3%$17.73$18.60$17.50247,100
$17.70-0.13-0.7%$17.75$18.33$17.50283,400
$17.83+0.13+0.7%$17.72$18.28$17.31285,500
$17.70-0.27-1.5%$18.00$18.82$17.57221,000
$17.97+0.19+1.1%$17.78$18.75$17.57350,800
$17.78+0.10+0.6%$17.70$18.19$17.06688,500
$17.68+0.35+2.0%$17.13$18.10$16.64420,200
$17.33-1.25-6.7%$18.33$18.70$17.20705,600
$18.58-0.47-2.5%$19.05$19.57$18.011,034,900
$19.05+0.80+4.4%$18.25$19.40$17.30913,900
$18.25-1.29-6.6%$19.31$19.53$17.85937,000
$19.54-0.40-2.0%$19.99$20.77$18.99962,200
$19.94-0.70-3.4%$20.65$21.61$19.23788,800
$20.64+0.55+2.7%$19.90$21.50$19.511,299,400
$20.09+0.74+3.8%$19.00$21.77$18.501,205,200
$19.35——$22.10$23.21$19.004,213,100
Ticker
NASDAQ:ADRX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All ADARx Pharmaceuticals, Inc. news

ADARx Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
4 in the last 12 months · 4 in all · newest Nov 12, 2026 · oldest 2026
Decks
2 decks · latest Nov 12, 2026

Where ADARx Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ADRX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ADRXBOATSUnited StatesUSD

Valuation

EV/sales 77.6× against a median of 9.5×: 6th lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$521.8M USD
P/E
Loss
EV/sales
77.6×
EV/EBITDA
Negative EBITDA
Price/book
2.5×
Gross margin
−231.0%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
Under 6 months of closes

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
ADARx Pharmaceuticals, Inc. · NASDAQ:ADRXUS$1.42BUS$521.8Mn/a77.6×n/a2.5×n/a0.0×n/a
Mesoblast Limited · ASX:MSBUS$1.46BUS$1.42Bn/a82.4×n/a2.4×−593.9%0.2×n/a
Voronoi, Inc. · KRX:310210US$1.44BUS$1.40Bn/an/an/a27.9×n/a0.5×n/a
Damora Therapeutics, Inc. · NASDAQ:DMRAUS$1.44BUS$910.0Mn/an/an/a2.9×n/a0.0×0.88
Vir Biotechnology, Inc. · NASDAQ:VIRUS$1.44BUS$1.07Bn/a3.5×n/a1.6×−61.0%0.1×1.82
LigaChem Biosciences Inc. · KRX:141080US$1.43BUS$1.15Bn/a15.5×n/a4.8×−180.9%0.0×n/a
Kailera Therapeutics, Inc. · NASDAQ:KLRAUS$1.43BUS$539.5Mn/an/an/a1.4×n/a0.0×1.28
Sarepta Therapeutics, Inc. · NASDAQ:SRPTUS$1.43BUS$1.41Bn/a0.7×n/a0.9×−5.9%0.6×1.70
Nurix Therapeutics, Inc. · NASDAQ:NRIXUS$1.40BUS$683.6M4.8×1.0×n/a1.4×42.0%0.0×1.15
Intellia Therapeutics, Inc. · NASDAQ:NTLAUS$1.40BUS$1.00Bn/a19.0×n/a2.3×−805.7%0.1×2.01
Tyra Biosciences, Inc. · NASDAQ:TYRAUS$1.39BUS$694.9Mn/an/an/a2.0×n/a0.0×0.40
Median of the othersUS$1.43BUS$1.04B4.8×9.5×2.1×−121.0%0.1×1.28

Forecasts

3 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
34.25 USD · Analysts' mean
EPS, year to Dec 2026
-2.01 · 3 analysts
Revenue, year to Dec 2026
6.53M · 5 analysts

Team and board

Officers

OfficerRole
Zhen LiPresident & CEO
Ryan FiskChief Financial Officer and Chief Business Officer
Christopher ClaeboeSenior Vice President of Operations
Mary TagliaferriChief Medical Officer and SVP at Nektar Therapeutics
Carl GordonCo-head Global Private Equity at OrbiMed Advisors
Rob AcklesChief People Officer
Robert A. MacLeodChief Scientific Officer
Rui ZhuChief Technology Officer

Board

DirectorRole
Carl GordonCo-head Global Private Equity at OrbiMed Advisors
Erez ChimovitsPartner at OrbiMed Advisors
Mary TagliaferriChief Medical Officer and SVP at Nektar Therapeutics
Simeon GeorgeDirector
Ying HuangBoard Member
Zhen LiPresident & CEO

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close−4.8%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (November 2026)Corporate update33 slidesNov 12, 2026
IPO Roadshow (September 2026)IPO roadshow35 slidesSeptember 2026

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$17 a share · J.P. Morgan +4
Dealers: J.P. Morgan (co-lead), Morgan Stanley (co-lead), TD Cowen (co-lead), UBS Investment Bank (co-lead), LifeSci Capital
Oct 1, 2026
Private placement of common stock
Closed: US$17 a share
Buyers: AbbVie (5,255,542 shares of common stock at $17.00 per share)
Oct 1, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$17.00 a share on Sep 24, 2026.

Price
US$17.00 a share
Shares offered
26,250,000 shares of common stock
Offering size
US$446.3 million
Underwriters' option
Up to 3,937,500 more shares
Listing
ADRX on the Nasdaq Global Select Market
Underwriters
J.P. Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank, LifeSci Capital · In the order on the cover
Shares delivered
On or about Sep 28, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceJun 22, 2026
Filed publiclySep 4, 2026
Amended twiceNewest Sep 21, 2026
Shares registered with an exchangeSep 22, 2026
Declared effective by the SECSep 24, 2026
Final prospectus, with the priceSep 28, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Sep 28, 2026

Financials

Annual, in USD

Income statement

LineFY2025FY2024
Revenue3.45M0
Gross profit3.45M
Research and development71.5M43.4M
Selling, general and administrative20.3M14.9M
Operating income-88.4M-58.2M
Depreciation and amortization2.33M1.50M
EBITDA-86.0M-56.7M
Income before tax-73.1M-46.4M
Net income-73.1M-46.4M
Earnings per share, basic-0.97-0.45

Balance sheet

LineFY2025FY2024
Cash and equivalents66.5M14.0M
Short-term investments413.5M205.4M
Current assets493.4M225.7M
Total assets507.7M233.5M
Accounts payable5.84M1.35M
Current liabilities30.5M8.94M
Total debt7.74M
Total liabilities709.9M370.6M
Shareholders' equity-202.3M-137.1M
Shares outstanding75.3M102.2M

Cash flow

LineFY2025FY2024
Cash from operations262.3M-48.6M
Capital spending-2.94M-455.0K
Free cash flow259.4M-49.0M
Cash from investing-209.9M
Cash from financing97.0K225.0K
Change in cash52.5M-8.82M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 16, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeOct 5, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeOct 2, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 1, 2026Big-stake noticeSEC
4 · Change in ownershipSep 30, 2026Insider tradeSEC
4 · Change in ownershipSep 30, 2026Insider tradeSEC
All 51 filings
FilingDateTypeFiled with
4 · Change in ownershipSep 30, 2026Insider tradeSEC
4 · Change in ownershipSep 29, 2026Insider tradeSEC
4 · Change in ownershipSep 29, 2026Insider tradeSEC
4 · Change in ownershipSep 29, 2026Insider tradeSEC
S-8 · Registration statement for employee plansSep 28, 2026Offer documentSEC
4 · Change in ownershipSep 28, 2026Insider tradeSEC
4 · Change in ownershipSep 28, 2026Insider tradeSEC
4 · Change in ownershipSep 28, 2026Insider tradeSEC
4 · Change in ownershipSep 28, 2026Insider tradeSEC
4 · Change in ownershipSep 28, 2026Insider tradeSEC
8-K · Current reportSep 28, 2026FinancingSEC
424B4 · ProspectusSep 25, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 25, 2026Other filingsSEC
3 · Initial statement of ownershipSep 24, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 24, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 24, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 24, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 24, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 24, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 24, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 24, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 24, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 24, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 24, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 24, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 24, 2026Insider tradeSEC
S-1MEF · Registration of more shares for the same offeringSep 24, 2026Offer documentSEC
CERT · Exchange's certificate of listingSep 24, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeSep 22, 2026Other filingsSEC
S-1/A · Registration statement, amendedSep 21, 2026Offer documentSEC
S-1/A · Registration statement, amendedSep 14, 2026Offer documentSEC
S-1 · Registration statementSep 4, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedJul 31, 2026Offer documentSEC
DRS · Draft registration statementJun 22, 2026Offer documentSEC
DAug 10, 2023Other filingsSEC
DJan 26, 2023Other filingsSEC
DAug 17, 2021Other filingsSEC
DMay 21, 2021Other filingsSEC
DNov 16, 2020Other filingsSEC
DAug 6, 2020Other filingsSEC
DFeb 5, 2020Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from ADARx Pharmaceuticals, Inc.’s releases · as of Oct 1, 2026

Common shares
110,738,825
Fully diluted
110,738,825

Fully diluted

LineSharesAs of
Common shares110,738,825Oct 1, 2026

Share count over time

CountShares
Nov 22, 2026110,738,825
Oct 1, 2026116,449,005
Oct 1, 2026111,193,463
Sep 30, 2026107,255,963

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Orbimed Advisors LLC24.2M21.9%US$483MSep 30, 2026
Sr One Capital Management, LP9.94M9.0%US$198MSep 30, 2026
Bain Capital Life Sciences Investors, LLC6.73M6.1%US$134MSep 30, 2026
T. Rowe Price4.5M4.1%US$89.7MSep 30, 2026
TCG Crossover Management, LLC4.12M3.7%US$82.1MSep 30, 2026
Fidelity3.65M3.3%US$72.7MSep 30, 2026
Capital Group3.33M3.0%US$66.4MSep 30, 2026
BlackRock2.34M2.1%US$46.6MSep 30, 2026
Siren, L.L.C.1.93M1.7%US$38.4MSep 30, 2026
AllianceBernstein1.72M1.6%US$34.3MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Venrock Adviser, LLC1.63M1.5%US$32.4MSep 30, 2026
Woodline Partners LP1.46M1.3%US$29.2MSep 30, 2026
Marshall Wace, LLP1.33M1.2%US$26.6MSep 30, 2026
Commodore Capital LP1.26M1.1%US$25.1MSep 30, 2026
EcoR1 Capital, LLC1.15M1.0%US$22.9MSep 30, 2026
Cormorant Asset Management, LP963K0.87%US$19.2MSep 30, 2026
Franklin Templeton900K0.81%US$13.5MSep 30, 2026
Redmile Group, LLC769K0.69%US$15.3MSep 30, 2026
Sun Life650K0.59%US$13MSep 30, 2026
GordonMD Global Investments LP450K0.41%US$8.97MSep 30, 2026
Millennium432K0.39%US$8.62MSep 30, 2026
Blackstone Inc.422K0.38%US$8.41MSep 30, 2026
Citadel341K0.31%US$6.8MSep 30, 2026
Rtw Investments, LP300K0.27%US$5.98MSep 30, 2026
Braidwell LP300K0.27%US$5.98MSep 30, 2026
Perceptive Advisors LLC300K0.27%US$5.98MSep 30, 2026
Vivo Capital, LLC255K0.23%US$5.09MSep 30, 2026
Goldman Sachs181K0.16%US$3.62MSep 30, 2026
Seven Grand Managers, LLC149K0.13%US$2.98MSep 30, 2026
abrdn120K0.11%US$2.39MSep 30, 2026
NEXTBio Capital Management LP100K0.09%US$1.99MSep 30, 2026
TD91,7700.08%US$1.89MSep 30, 2026
Man Group plc78,1680.07%US$1.56MSep 30, 2026
Balyasny Asset Management L.P.72,6880.07%US$1.45MSep 30, 2026
Jane Street63,6800.06%US$1.27MSep 30, 2026
Vanguard55,0000.05%US$1.1MSep 30, 2026
Stempoint Capital LP52,0000.05%US$1.04MSep 30, 2026
ExodusPoint Capital Management, LP50,7300.05%US$1.01MSep 30, 2026
Hrt Financial LP50,2110.05%US$1MSep 30, 2026
Alyeska Investment Group, L.P.50,0000.05%US$997KSep 30, 2026
Aristeia Capital, L.L.C.42,0000.04%US$837KSep 30, 2026
Prelude Capital Management, LLC38,8000.04%US$774KSep 30, 2026
Readystate Asset Management LP25,0000.02%US$499KSep 30, 2026
Ghisallo Capital Management LLC25,0000.02%US$499KSep 30, 2026
Morgan Stanley22,5440.02%US$450KSep 30, 2026
Jump Financial, LLC20,7720.02%US$414KSep 30, 2026
Burkehill Global Management, LP20,0000.02%US$399KSep 30, 2026
Laurion Capital Management LP20,0000.02%US$399KSep 30, 2026
Longaeva Partners L.P.15,0000.01%US$299KSep 30, 2026
Landscape Capital Management, L.L.C.14,8310.01%US$296KSep 30, 2026

This page holds 50 of 57 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
OrbiMed Genesis GP LLC
Director, 10% owner
Buy300,249USD 17.00US$5.1MSep 28, 2026
OrbiMed Genesis GP LLC
Director, 10% owner
Buy61,516USD 17.00US$1.05MSep 28, 2026
OrbiMed Genesis GP LLC
Director, 10% owner
Buy588,235USD 17.00US$10MSep 28, 2026
Gordon Carl L
Director, 10% owner
Buy300,249USD 17.00US$5.1MSep 28, 2026
Gordon Carl L
Director, 10% owner
Buy61,516USD 17.00US$1.05MSep 28, 2026
Gordon Carl L
Director, 10% owner
Buy588,235USD 17.00US$10MSep 28, 2026
Chimovits Erez
Director
Buy61,516USD 17.00US$1.05MSep 28, 2026
George Simeon
Director, 10% owner
Buy414,814USD 17.00US$7.05MSep 28, 2026
George Simeon
Director, 10% owner
Buy592,593USD 17.00US$10.1MSep 28, 2026
SR One Capital Management, LLC
10% owner
Buy414,814USD 17.00US$7.05MSep 28, 2026
All 11 trades
TradeTradeSharesPriceValueDate
SR One Capital Management, LLC
10% owner
Buy592,593USD 17.00US$10.1MSep 28, 2026

Big stakes

StakeStakeSharesDateFiling
ORBIMED ADVISORS LLC14.00%14.9MSep 28, 2026Schedule 13D
Yi Shi11.10%11.9MSep 30, 2026Schedule 13G
Zhen Li9.60%10.8MSep 30, 2026Schedule 13G
SR One Capital Management, LLC9.30%9.94MSep 28, 2026Schedule 13D
BCLS Fund III Investments, LP6.30%6.73MSep 24, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Simeon George
Other companies: Design Therapeutics, Inc. (Director · Since at least Jun 15, 2022); CRISPR Therapeutics AG (Director · Since at least Jun 9, 2022); Nkarta, Inc. (Director · Since at least Apr 28, 2022); Turning Point Therapeutics Inc (Director · Aug 17, 2022 – Aug 17, 2022 · Past)
Director · Since at least Sep 24, 2026
Mary Tagliaferri
Other companies: Y mAbs Therapeutics (Director · Feb 29, 2024 – Jun 11, 2024 · Past); RayzeBio, Inc. (Director · Sep 14, 2023 – Feb 26, 2024 · Past); Enzo Biochem Inc (Director · Nov 17, 2020 – Jan 31, 2024 · Past)
Chief Medical Officer and SVP at Nektar Therapeutics · Since at least Sep 24, 2026
Carl L. Gordon
Other companies: Electra Therapeutics, Inc. (Director · Since at least Sep 21, 2026); BlossomHill Therapeutics, Inc. (Director · Since at least Aug 10, 2026)
Director · Since at least Sep 28, 2026
Ying Huang
Other companies: TCGX Acquisition Corp. (Director · Since at least Aug 4, 2026); Legend Biotech Corp. (Chief Executive Officer, Director · Since at least Mar 18, 2026)
Board Member · Since at least Sep 24, 2026
Erez Chimovits
Other companies: Braveheart Bio, Inc. (Director · Since at least Aug 7, 2026)
Director · Since at least Sep 28, 2026
Alan Robert MacLeodChief Scientific Officer · Since at least Sep 24, 2026
Christopher ClaeboeSenior Vice President of Operations · Since at least Nov 4, 2026
Rob AcklesChief People Officer · Since at least Nov 4, 2026
Robert A. MacLeodChief Scientific Officer · Since at least Nov 4, 2026
Robert William AcklesChief People Officer · Since at least Sep 24, 2026
All 13 people
PersonSeat
Rui ZhuChief Technology Officer · Since at least Sep 24, 2026
Ryan FiskCFO and CBO · Since at least Sep 24, 2026
Zhen LiPresident and CEO, Director · Since at least Sep 24, 2026

Open People

Log in to ask 6ix AI your own questions about ADARx Pharmaceuticals, Inc.